Plenary posters

April 2005
Gut;Apr2005 Supplement 2, Vol. 54, pA33
Academic Journal
The article presents information on abstracts related to human biology. An abstract sheds light on reducing inappropriate use of intravenous proton pump inhibitors with a cost effective guideline. Hospital intravenous (IV) proton pump inhibitors (PPI) use was unrestricted within licensed indications. Monitoring prescribing trends, pharmacists observed IVI PPI use was increasing. The clinical indications for lVI PPI were reviewed during the development of IVI PPI guidelines. A randomized sample retrospective case note review was performed on patients identified by pharmacy as receiving IV PRI in a six month period before IVI PPI guidelines were introduced. The guideline was promoted via the consultant gastroenterology staff, memoranda to wards, in ward formularies, and by "policing" from ward pharmacists. Following guideline introduction a prospective audit was performed on all patients issued with IV PPIs.


Related Articles

  • Rabeprazole: A Viewpoint by Noriaki Takeguchi. Takeguchi, N. // Drugs;Feb1998, Vol. 55 Issue 2, p268 

    Presents a viewpoint on the efficacy of rabeprazole against acid-related disorders. Mechanism of action of the medication; Characteristics as a proton pump inhibitor.

  • Rabeprazole: A Viewpoint by Simmy Bank. Bank, S. // Drugs;Feb1998, Vol. 55 Issue 2, p268 

    Presents a viewpoint on the efficacy of rabeprazole against acid-related disorders. Mechanism of action; Characteristics as a proton pump inhibitor; Results of clinical trials on the medication.

  • Clinical Pharmacology of Proton Pump Inhibitors: What the Practising Physician Needs to Know. Robinson, Malcolm; Horn, John // Drugs;2003, Vol. 63 Issue 24, p2739 

    Proton pump inhibitors (PPIs) [omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole] are widely utilised for the treatment of gastro-oesophageal reflux disease, as well as other acid-related disorders. All PPIs suppress gastric acid secretion by blocking the gastric acid pump,...

  • Pharmacokinetics of Tenatoprazole, a Newly Synthesized Proton Pump Inhibitor, in Healthy Male Caucasian Volunteers. Domagala, Florence; Ficheux, Hervé; Houin, Georges; Barré, Jérôme // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Jan2006, Vol. 56 Issue 1, p33 

    The pharmacokinetics of tenatoprazole (CAS 113712-98-4), a newly synthesized proton pump inhibitor, and its metabolites TU-501 (sulfide form) and TU-502 (sulfone form) were investigated in an ascending-dose parallel-group study at the dose levels of 10, 20, 40, 80 and 120 mg. A total of 30...

  • Intravenous Lansoprazole: A Viewpoint by Malcolm Robinson. Robinson, Malcolm // Drugs;2004, Vol. 64 Issue 18, p2090 

    Proton pump inhibitor (PPI) lansoprazole is now available in an intravenous (IV) formulation in North America. PPI work by inhibiting active proton pumps and are most effective when administered with meals. Hospitalized patients who received IV PPI are fasting and they may be expected to be...

  • Proton Pump Inhibitors: Do Differences in Pharmacokinetics Translate into Differences in Clinical Outcomes? Kwong Ming Fock; Tiing Leong Ang; Lean Choo Bee; Jon Deon Lee, Edmund // Clinical Pharmacokinetics;2008, Vol. 47 Issue 1, p1 

    Acid-related disorders are common management problems in clinical practice. The key to effective management is successful suppression of gastric acid production. Proton pump inhibitors (PPIs) are the most potent acid suppressants available and are significantly more effective than histamine H2...

  • Is double-dose PPI use warranted in upper GI symptoms?  // PharmacoEconomics & Outcomes News;8/9/2008, Issue 559, p10 

    The article discusses research being done on proton pump inhibitors (PPI). It references a study by L. E. Targownik et al, published in a June 2008 issue of "Digestive Diseases and Sciences." Canadian researchers found that initial prescription of double-dose PPI did not lead to a reduction in...

  • Study supports NICE on dyspepsia. Baines, Emma // GP: General Practitioner;5/24/2004, p19 

    Treatment with a proton pump inhibitor (PPI) followed by test-and-treat for Helicobacter pylori is the best strategy for managing patients with dyspepsia, according to Dutch research. The findings support recommendations made by NICE in its draft guidance on the management of chronic dyspepsia,...

  • Proton Pump Inhibitors and Acid Pump Antagonists. Jai Moo Shin; Wallmark, Björn; Sachs, George // Encyclopedic Reference of Molecular Pharmacology;2004, p771 

    The article presents an encyclopedia entry for proton pump inhibitors and acid pump antagonists. It can be classified into reversible and non-reversible covalent inhibitors. The covalent binding inhibitors are substituted 2-benzimidazoles and the reversible inhibitors are K+-competitive. The PPI...


Read the Article


Sign out of this library

Other Topics